Article citationsMore>>

Miller, R.E., Leary, A., Scott, C.L., Serra, V., Lord, C.J., Bowtell, D., et al. (2020) ESMO Recommendations on Predictive Biomarker Testing for Homologous Recombination Deficiency and PARP Inhibitor Benefit in Ovarian Cancer. Annals of Oncology, 31, 1606-1622.
https://doi.org/10.1016/j.annonc.2020.08.2102

has been cited by the following article:

• TITLE: Adverse Reactions Such as Fecal Incontinence Occurred in 1 Patient with Ovarian Cancer Induced by Paclitaxel Liposome Allergy

  AUTHORS: Gaijing Wang, Haimei Ren, Ziyi Liu, Jing Wang, Lei Su, Miaomiao Song, Yanling Li, Yuanyuan Yang, Jiale Lu, Zhihui Cai, Jie Cui

  KEYWORDS: Paclitaxel, Drug Allergy, Adverse Reactions, Ovarian Cancer

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.1, January 10, 2025

  ABSTRACT: Paclitaxel is one of the commonly used drugs in postoperative chemotherapy for ovarian cancer patients. However, affected by drug dosage and individual differences in the course of medication, patients will have different degrees of adverse reactions, which will cause damage to the patient’s body once they occur. This paper retrospectively analyzed the clinical data of patients with severe allergic reactions such as fecal incontinence and numbness of hands and feet caused by the use of paclitaxel liposome during postoperative chemotherapy in a case of ovarian cancer admitted to our hospital. The causes and corresponding treatment measures were analyzed, in order to provide the reference for medical staff to take effective countermeasures in advance in the future.